We are live on ! Find out more

441 hedge funds and large institutions have $15.3B invested in Insmed in 2025 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 185 increasing their positions, 151 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 185 | Existing positions reduced: 151

17% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 48

15% more capital invested

Capital invested by funds: $13.3B → $15.3B (+$2.01B)

7% more funds holding in top 10

Funds holding in top 10: 2931 (+2)

2.65% more ownership

Funds ownership: 107.64%110.29% (+2.7%)

1% more funds holding

Funds holding: 438441 (+3)

50% less call options, than puts

Call options by funds: $73M | Put options by funds: $145M

Holders
441
Holders Change
+3
Holders Change %
+0.68%
% of All Funds
5.91%
Holding in Top 10
31
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+6.9%
% of All Funds
0.42%
New
56
Increased
185
Reduced
151
Closed
48
Calls
$73M
Puts
$145M
Net Calls
-$72M
Net Calls Change
-$110M
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$128M -$5.11M -66,804 -4%
Charles Schwab
27
Charles Schwab
California
$122M +$4.29M +56,048 +4%
Janus Henderson Group
28
Janus Henderson Group
United Kingdom
$121M +$7.63M +99,723 +7%
HRCM
29
Hood River Capital Management
Florida
$119M +$2.5M +32,658 +2%
IHAM
30
Integral Health Asset Management
New York
$118M
SCM
31
Suvretta Capital Management
New York
$114M -$9.12M -119,178 -7%
T. Rowe Price Investment Management
32
T. Rowe Price Investment Management
Maryland
$113M -$38.7M -505,759 -26%
Westfield Capital Management
33
Westfield Capital Management
Massachusetts
$107M +$35.8M +468,058 +50%
Goldman Sachs
34
Goldman Sachs
New York
$107M -$24.3M -317,428 -18%
GKIM
35
GW&K Investment Management
Massachusetts
$105M +$18.5M +242,333 +21%
DFO
36
Duquesne Family Office
New York
$104M +$59.3M +775,580 +131%
Bank of America
37
Bank of America
North Carolina
$103M +$18.8M +245,333 +22%
Lord, Abbett & Co
38
Lord, Abbett & Co
New Jersey
$103M -$8.16M -106,623 -7%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$93.3M +$36M +470,401 +63%
EAM
40
Eventide Asset Management
Massachusetts
$90.2M +$6.17M +80,682 +7%
N
41
Nuveen
North Carolina
$88.4M -$8.3M -108,536 -9%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$88.2M -$21.5M -281,716 -20%
VPC
43
Vestal Point Capital
New York
$82M +$13.4M +175,000 +19%
TCM
44
TimesSquare Capital Management
New York
$81.2M +$29M +379,764 +55%
Morgan Stanley
45
Morgan Stanley
New York
$80.8M -$22.3M -291,709 -22%
Loomis, Sayles & Company
46
Loomis, Sayles & Company
Massachusetts
$77M -$12.6M -165,325 -14%
PAI
47
Palo Alto Investors
California
$75.3M -$47.1M -616,312 -38%
American Century Companies
48
American Century Companies
Missouri
$66.5M +$4.54M +59,343 +7%
Jennison Associates
49
Jennison Associates
New York
$57.1M -$1.95M -25,500 -3%
Alyeska Investment Group
50
Alyeska Investment Group
Illinois
$56.1M -$15.4M -200,779 -21%

INSM Hedge Fund Activity: Q1 2025 in Review

441 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2025, worth a combined $15.3B — up 15% from $13.3B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new INSM positions and 48 closed out — a net gain of 8 holders — while 185 added to existing stakes and 151 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $235M. The largest seller was Fidelity Investments, cutting an estimated $112M.

  • 441 institutional investors held Insmed (INSM) as of Q1 2025, up from 438 in Q4 2024.
  • Funds reported $15.3B of Insmed stock for Q1 2025, up 15% quarter-over-quarter.
  • 56 funds opened new Insmed positions in Q1 2025 and 48 closed out, a net change of +8 holders.
  • The largest Insmed buyer in Q1 2025 was JP Morgan Chase, an estimated $235M added.
  • The largest Insmed seller in Q1 2025 was Fidelity Investments, an estimated $112M sold.

Based on aggregated 13F filings for Q1 2025.